SCHEMBL6236219

SCHEMBL6236219

N#Cc1cc(CBr)ccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 5/20 0.46
MAPT P10636 5/20 0.44
GRIA1 P42261 2/20 0.44
GRIA2 P42262 2/20 0.44
GRIA3 P42263 2/20 0.44
GRIA4 P48058 2/20 0.44
GRM6 O15303 1/20 0.44
CYP1A2 P05177 1/20 0.44
ALOX15 P16050 1/20 0.44
HPGD P15428 2/20 0.43
POLB P06746 2/20 0.43
CYP2C9 P11712 1/20 0.43
APEX1 P27695 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP19A1 P11511 2/20 0.39
ALDH1A1 P00352 3/20 0.38
HTT P42858 1/20 0.38
GPR35 Q9HC97 1/20 0.38
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3921931 0.87 VCAM1 (0.58) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL9798297 0.84 VCAM1 (0.39) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL9798291 0.84 VCAM1 (0.39) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL16956496 0.83 VCAM1 (0.46) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL29151814 0.82 GRIA1 (0.46) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL855859 0.81 VCAM1 (0.42) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL22664328 0.80 VCAM1 (0.43) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL29100217 0.78 VCAM1 (0.45) VCAM1MAPTGRIA1GRIA2GRIA3
SCHEMBL1117240 0.78 TSHR (0.50) MAPTGRIA1GRIA2GRIA3GRIA4
SCHEMBL1372821 0.78 ALDH1A1 (0.40) VCAM1MAPTGRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081338-A1 METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION CHELSEA THERAPEUTICS, INC. 2011-04-07 US disclosed
US-20110082149-A1 METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION CHELSEA THERAPEUTICS, INC. 2011-04-07 US disclosed
EP-1535911-A1 Metabolically inert anti-inflammatory and anti-tumor antifolates NAIR, Madhavan G. (US) 2005-06-01 EP disclosed
EP-1062209-A4 METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES NAIR MADHAVAN G (US) 2002-02-27 EP disclosed
EP-1062209-A1 METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES NAIR, Madhavan G. (US) 2000-12-27 EP disclosed
WO-1999036409-A1 METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES NAIR MADHAVAN G (US) 1999-07-22 WO disclosed
US-5912251-A ENZYME INHIBITORS CHELSEA THERAPEUTICS, INC. 1999-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081338-A1 METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION DHFR, MTHFD1, MTHFD2 VCAM1 1416/4885MAPT 816/4885GRIA1 3613/4885
US-20110082149-A1 METABOLICALLY INERT ANTIFOLATES FOR TREATING DISORDERS OF ABNORMAL CELLULAR PROLIFERATION AND INFLAMMATION DHFR, MTHFD1, MTHFD2 VCAM1 1416/4885MAPT 816/4885GRIA1 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.